Cibus (NASDAQ:CBUS – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Cibus to similar businesses based on the strength of its profitability, institutional ownership, valuation, dividends, analyst recommendations, risk and earnings.
Earnings & Valuation
This table compares Cibus and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cibus | $3.64 million | -$127.08 million | -0.81 |
| Cibus Competitors | $718.90 million | $8.79 million | -18.19 |
Cibus’ competitors have higher revenue and earnings than Cibus. Cibus is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Analyst Recommendations
This is a summary of current ratings and recommmendations for Cibus and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cibus | 1 | 1 | 1 | 0 | 2.00 |
| Cibus Competitors | 9926 | 15341 | 45758 | 1601 | 2.54 |
Cibus presently has a consensus target price of $9.00, suggesting a potential upside of 640.74%. As a group, “Biotechnology” companies have a potential upside of 111.81%. Given Cibus’ higher probable upside, research analysts clearly believe Cibus is more favorable than its competitors.
Profitability
This table compares Cibus and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cibus | -2,131.38% | -526.66% | -28.12% |
| Cibus Competitors | -12,516.26% | -215.37% | -31.41% |
Insider and Institutional Ownership
33.8% of Cibus shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 29.9% of Cibus shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Cibus competitors beat Cibus on 7 of the 13 factors compared.
About Cibus
Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant’s own genes, with the goal of developing useful crop characteristics without adding foreign DNA. The company’s research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.
